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Olanzapine vs. conventional and other atypical antipsychotics in response and 
side effects for the treatment of schizophrenia 
Abstract 
The efficacy and side effects of olanzapine (an atypical antipsychotic) for the treatment of Schizophrenia 
were compared over ten different studies. The methods, findings, and limitations of olanzapine treatment 
when compared to conventional antipsychotics, monotherapy atypical antipsychotics, and combination 
atypical antipsychotics were addressed. These studies looked at populations of people with first-episode 
Schizophrenia, chronic cases, and resistant positive and negative symptoms. Olanzapine showed to have 
an equal to or greater decrease in negative symptoms and also an equal to or greater reduction in positive 
symptoms. Olanzapine also showed to have a reduction in extrapyramidal symptoms and an increase in 
neurocognitive functioning, response rates, compliance, and quality oflife. However, olanzapine did have 
negative side effects such as: significant weight gain, increase in blood pressure and cholesterol, and a 
decrease in liver function. 
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Abstract 
The efficacy and side effects of olanzapine (an atypical antipsychotic) for the treatment 
of Schizophrenia were compared over ten different studies. The methods, findings, and 
limitations of olanzapine treatment when compared to conventional antipsychotics, 
monotherapy atypical antipsychotics, and combination atypical antipsychotics were 
addressed. These studies looked at populations of people with first-episode 
Schizophrenia, chronic cases, and resistant positive and negative symptoms. Olanzapine 
showed to have an equal to or greater decrease in negative symptoms and also an equal to 
or greater reduction in positive symptoms. Olanzapine also showed to have a reduction 
in extrapyramidal symptoms and an increase in neurocognitive functioning, response 
rates, compliance, and quality oflife. However, olanzapine did have negative side effects 
such as: significant weight gain, increase in blood pressure and cholesterol, and a 
decrease in liver function. 
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Olanzapine vs. Conventional and Other Atypical Antipsychotics in 
Response and Side Effects for the Treatment of Schizophrenia 
Olanzapine is a new-generation (atypical) antipsychotic agent that is hypothesized 
to have superior efficacy. This medication is sold under the brand name Zyprexa. This 
research update will discuss the findings, methods, and limitations of the treatment 
outcomes of olanzapine versus other atypical and conventional agents. This paper will 
compare results of studies with topics such as treatment of; first-episode schizophrenia, 
chronic cases of schizophrenia, and resistant positive and negative symptoms. It will also 
contrast the information to understand the results and determine if olanzapine does have 
greater efficacy based on the presented studies. 
Article Summaries 
Robinson, D. G., et al. 
In a stratified, randomized controlled trial treatment in two non-for-profit 
facilities who both serve low-to-middle class and one serving mostly minority population, 
Robinson et al. compared treatment outcomes for comparable doses (open-label) of either 
olanzapine or risperidone. Symptom response (response rates, positive and negative 
symptoms) and side effects (weight gain and extrapyramidal symptoms) were compared 
between the two medications for four months on 112 subjects in their first episode of 
schizophrenia. Response rates were similar between both olanzapine and risperidone 
with almost twice as many subjects who responded to olanzapine later not meeting 
criteria for substantial improvement. There were no significant differences between 
medications for positive symptoms, both improving over time. Negative symptoms 
showed no significant differences in medications over time and only showed 
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improvement in avolition-apathy and asociality-anhedonia showing improvement. 
Olanzapine showed somewhat more favorable to risperidone in the appearance and 
treatment of extrapyramidal symptoms (rate of parkinsonism and akathisia). Although 
both medications showed significant weight increase overtime, olanzapine had a 
substantially greater increase than risperidone. Whether the reserved advantages in less 
extrapyramidal symptoms with olanzapine is worth the weight gain risks over risperidone 
need to be considered. One limitation of this study is that open-label assignment allows 
for possible patient or investigator bias. 
Buchanan, R. W. 
In a double-blind, parallel group comparison with subjects from two research 
programs, Buchanan et al. compared the effect on either positive or negative residual 
symptoms, social and functional outcomes, and side effects of treatment with comparable 
dosages (open-label) of either haloperidol (with prophylactic benztropine) and olanzapine 
(with a benztropine placebo). The study consisted of a 16-week treatment for 63 
outpatients experiencing residual positive or negative symptoms of schizophrenia or 
schizoaffective disorder. In biweekly assessments there was no overall significant 
difference between olanzapine and haloperidol in their effects on positive or negative 
symptoms, or on the. measures of social and functional outcome. Olanzapine treated 
subjects showed a significant decrease in extrapyramidal symptom specific to dry mouth 
and stiffness. The olanzapine group also had significant increases in systolic blood 
pressure and weight compared to haloperidol. Whether the advantages in decreased 
extrapyramidal symptoms in olanzapine are worth the weight gain and increase in 
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systolic blood pressure over haloperidol need to be considered. One limitation of this 
study is the number of subjects is relatively small. 
Bilder, R. M 
In a double blind, four comparison group study with subjects from four state psychiatric 
hospitals, Bilder et al. compared the neurocognitive effects of comparable dosages of 
either clozapine, olanzapine, risperidone or haloperidol (with prophylactic benztropine, 
placebo benztropine or a combination of both). The study consisted of a 14-week 
treatment for 101 inpatients diagnosed with either schizophrenia or schizoaffective 
disorder. Despite changes is symptoms ( clozapine, olanzapine, and risperdone all yielded 
significant decreases in symptoms), side effects, or blood levels, patients treated with 
olanzapine and risperidone had a significant improvement in neurocognitive function. 
Olanzapine showed to have the greatest improvement in the general and attention 
domains, risperidone with memory, and clozapine with motor function. Patients seemed 
to show an increase in neurocognitive functioning with the atypical antipsychotics as 
opposed to conventional and even different cognitive effects between the atypical 
antipsychotics. Which improvements would be most beneficial for each individual 
patient should be considered. One limitation to this study is how well it will generalize to 
patients who are more likely to have positive outcomes to treatment. 
Gurpegui, M. 
In a randomized, parallel group study in 21 centers in Spain Gurpegui et al. 
compared neurocognitive functioning, clinical symptoms, and social functioning with 
flexible dosages ( open-label) of either olanzapine or risperidone. The study consisted of 
a one-year trial in 235 outpatients with chronic schizophrenia with prominent negative 
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symptoms. There was an increase in neurocognitve functioning (while not significant) 
and a decrease in negative symptoms in both groups although there was not a significant 
difference between the risperidone group and the olanzapine group. Whether the 
decrease of negative symptoms alone is enough to proceed with an atypical antipsychotic 
needs to be determined. One limitation of this study is that th~ subjects had previous 
treatment with FGA that could have enhanced or reduced the outcomes was not counted 
for in the results. 
Bitter, I., Czobor, P., Dossenbach, M and Volavka, J. 
In a non-interventional, prospective observational study Bitter, Czobor, 
Dossenbach and Volavka compared hostile and aggressive behavior in monotherapy 
treatment groups prescribed clozapine, olanzapine, quetiapine, risperidone, or 
haloperidol. The study consisted of a 3-year trial (with data available on the first 6 
months) on 3135 outpatients with schizophrenia from over 27 countries from the 
International Schizophrenia Outpatient Health Outcomes (IC-SOHO). Hostile and 
aggressive behaviors were reduced in all treatment groups with olanzapine and 
risperidone having a significant decrease over haloperidol and the other atypical 
antipychotics. The results were consistent when baseline was adjusted for differences in 
age, gender, age of onset, and substance abuse. This study contradicts previous research 
stating clozapine has a significant decrease in aggressive behavior. Further research 
should be considered for the optimal treatment of schizophrenia, especially in patients 
with hostile/aggressive behavior. One limitation of this study is that open-label 
assignment allows for possible patient or investigator bias. 
Ritchi et al. 
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In a randomized open label study Ritchi et al. compared motor side effects, 
efficacy, safety and quality of life in treatment groups switched from their conventional 
antipsychotics to either olanzapine or risperidone. The study consisted of a time period 
for preparation to switch medications and a switching stage in 66 elderly patients with 
schizophrenia in eight centers in Australia. Both the olanzapine and risperidone groups 
had an improvement of negative symptoms and Parkinsonism with no significant 
difference between groups. Olanzapine was shown to significantly decrease dyskinetic 
symptoms, increase response rate, and improve the quality oflife over risperidone. 
Switching from a conventional antipsychotic to either olanzapine or risperidone show 
improvement in elderly patients with schizophrenia, but the lack of testing and discussion 
on other side effects emphasize the need from further research. One limitation of this 
study is that there was a high rate of comorbid illness and concurrent, non-psychiatric 
medication use. 
Wood et al. 
In a randomized, double blind parallel group study Woods et al. compared prodromal 
symptoms, extrapyramidal symptoms, and side effects in treatment groups prescribed 
either fixed-flexible doses of olanzapine or placebo. The study consisted of an 8-week 
trial in 60 patients who met the criteria for schizophrenic prodromal symptoms in four 
separate sites in North America. There was a significantly greater improvement in 
symptoms with the olanzapine group than the placebo group. Both groups had similar 
minimal extrapyramidal symptoms and the differences between groups were not 
significantly different. Olanzapine did have a significant increase in weight gain over the 
placebo group. Additional research with a longer time frame needs to be assessed before 
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routine treatment is implemented. An important limitation of this study is the small 
sample size. 
Green et al. 
In a randomized, double blind international study Green et al. compared symptom 
severity, compliance, and remission rates in treatment groups prescribed either 
olanzapine or haloperidol. This study consisted of a 2-year trial on 263 patients with 
first-episode psychosis from 14 academic medical centers. Decreases in symptom 
severity in both haloperidol and olanzapine were significant and comparable to each 
other. Treatment with olanzapine showed significant increase compared to haloperidol 
in compliance and remission rates. Haloperidol showed an increase in extrapyramidal 
side effects while olanzapine showed an increase in weight gain, cholesterol level and a 
decrease in liver functions. Whether the compliance and remission rate advantages of 
olanzapine over haloperidol outweigh the side effects of the medications should be 
carefully considered. One limitation of this study is that after randomization the groups 
at baseline were not equal on the duration of their illness, which the researchers deemed 
important. 
Hofer, A. et al. 
In a between-group comparison study Hofer et al. compared positive and negative 
symptoms, neurocognitive functioning, functionality and subjective outcomes in 
treatment groups who had been prescribed either amisulpride or olanzapine for at least 6 
months. This study consisted of 60 outpatients with chronic schizophrenia. Treatment in 
both the amisulrpride and olanzapine groups were comparable in functional and 
subjective outcomes. Results were also similar in the scores of positive, negative, and 
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cognitive symptoms. Although comparable, olanzapine did show lower scores in 
depression/anxiety and excitement components and amisulrpride in verbal fluency. 
Although both atypical antipsychotics were similar, depending on specific treatment 
outcomes desired, more research is required. One limitation of this study is the number 
of subjects is relatively small. 
Ohleier, M. D., Jahn, K., Welhelm-Gossling, C., Godecke-Koch, T., and Hoffman, J. 
In a between-group comparison study Ohleier, Jahn, Welhelm-Gossling, 
Godecke-Koch, and Hoffmann compared positive and negative symptoms and 
neuropsychological state in treatment groups prescribed either perazine in combination 
with carbarnazepine or olanzapine (as a monotherapy). This study consisted of 3-week 
trial on 23 patients meeting the DSM-IV criteria for schizophrenia that were assessed 3 
times throughout the study. Negative symptoms and performance on cognitive tests 
improved in both groups and there was no significant difference between the groups. 
Olanzapine did show a superior response over the perazine in combination with 
carbamazepine group to positive symptoms. Although this research suggest a significant 
decrease in positive symptoms with olanzapine as a monotherapy, more research is 
needed to see if combination treatment is ideal for overall outcomes to treatment of 
schizophrenia. One limitation of this study is the relatively small duration of time and 
number of subjects. 
Synthesis 
In the ten studies presented olanzapine was the overall most effective treatment 
compared to conventional antipsychotics, monotherapy atypical antipsychotics, and 
combination atypical antipsychotics for patients with schizophrenia ( even in elderly 
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patients, patients with resistant symptoms, and patients suffering from chronic cases of 
schizophrenia.) In all of the studies (which used negative symptoms as one of the 
dependant variables, 9 of the 10 studies) olanzapine showed an equal to or greater than 
decrease in negative symptoms. In the seven studies that used positive symptoms as a 
dependant variable all seven showed olanzapine to be equal to or greater than the other 
medications or placebo in reducing the patients positive symptoms. The studies looking 
at extrapyramidal symptoms found that olanzapine was equal to or greater than the other 
groups in the reductions of these symptoms, with specific references to dyskinetic 
symptoms, Parkinsonism, stiffness and dry mouth. Olanzapine also showed a significant 
increase in neurocognitive functioning, with one study showing specific increase in 
general and attention domains. Olanzapine also showed an increase in response rates, 
remission rates, compliance, and quality of life. Two studies showed an increase in 
; 
social, functional, and subjective outcomes. One study also found a significant decrease 
in hostility/aggression factors. 
Although Olanzapine is shown to be equal to or superior to conventional or other 
atypical antipsychotics on many important factors it also showed to have a significant 
weight gain across studies as well as an increase in blood pressure and cholesterol and a 
decrease in liver function. 
Not unlike other studies, these studies have limitations and there is a need for 
further research. Whether the efficacy of olanzapine overshadows the negative side 
effects should be determined on a physician/patient basis. These studies do show 
olanzapine should be a highly recommended treatment medication for patients with 
schizophrenia for a wide range of improvement of symptoms. 
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